Carbimazole, Thiamazole (Methimazole)

Hearing loss / Auditory deficit

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S8483
R27820		 Yoshihara (Controls exposed to PTU), 2021 Congenital hearing loss 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 7.99 [0.32;201.71] C
excluded (control group) 		0/23   1/541 1 23
ref
S8482
R27798		 Yoshihara (Controls unexposed, sick), 2021 Congenital hearing loss 1st trimester retrospective cohort unexposed, sick Adjustment: No 2.99 [0.15;59.73] C 0/23   3/475 3 23
ref
S3353
R6005		 Yoshihara (control exposed to PTU), 2012 Hearing loss 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 3.41 [0.14;83.85] C
excluded (control group) 		1/1,231   0/1,399 1 1,231
ref
S3350
R5868		 Yoshihara (control unexposed, sick), 2012 Hearing loss 1st trimester retrospective cohort unexposed, sick Adjustment: No 4.65 [0.19;114.23] C 1/1,231   0/1,906 1 1,231
ref
Total 2 studies 3.68 [0.41;32.73] 4 1,254
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Yoshihara (Controls unexposed, sick), 2021Yoshihara, 2021 1 2.99[0.15; 59.73]32353%ROB confusion: criticalROB selection: moderateROB classification: unclearROB missing: unclearROB mesure: criticalROB reporting: moderate Yoshihara (control unexposed, sick), 2012Yoshihara, 2012 2 4.65[0.19; 114.23]11,23147%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: criticalROB reporting: moderate Total (2 studies) I2 = 0% 3.68[0.41; 32.73]41,2540.910.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick; 2: control unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 3.68[0.41; 32.73]41,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 3.68[0.41; 32.73]41,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 Tags Adjustment   - No  - No 3.68[0.41; 32.73]41,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 All studiesAll studies 3.68[0.41; 32.73]41,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 20.510.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 3353, 8483

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 3.68[0.41; 32.73]41,2540%NAYoshihara (Controls unexposed, sick), 2021 Yoshihara (control unexposed, sick), 2012 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 5.20[0.54; 50.54]21,2540%NAYoshihara (Controls exposed to PTU), 2021 Yoshihara (control exposed to PTU), 2012 20.510.01.0